➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
McKinsey
Dow
McKesson
Boehringer Ingelheim

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Litigation Details for IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. (D.N.J. 2019)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. (D.N.J. 2019)

Docket   Start Trial Date Filed 2019-04-30
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To Claire Claudia Cecchi
Jury Demand Plaintiff Referred To Mark Falk
Parties AMGEN MANUFACTURING, LIMITED; HOFFMANN-LA ROCHE INC.; IMMUNEX CORPORATION; SAMSUNG BIOEPIS CO., LTD.; SANDOZ INC.; SANDOZ GMBH; SANDOZ INTERNATIONAL GMBH
Patents 6,235,883; 6,858,409; 7,915,225; RE37,336; RE37,343
Attorneys CHARLES H. CHEVALIER; CHRISTINA LYNN SAVERIANO; CHRISTINE INTROMASSO GANNON; COLLEEN M. MAKER; DAVID E. DELORENZI; JUSTIN TAYLOR QUINN; KEITH J. MILLER; LIZA M. WALSH; MARC D. HAEFNER; SARAH ANN SULLIVAN; WILLIAM C. BATON
Firms Christina Lynn Saveriano; Robinson Miller LLC, Ironside Newark
Link to Docket External link to docket
Biologic Drugs cited in IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. (D.N.J. 2019)

Date Filed Document No. Description Snippet Link To Document
2019-04-30 1 Complaint “Roche Patents”); and • U.S. Patents Nos. 7,915,225 (“the ’225 Patent”), 8,119,605…United States Patent Nos. 8,063,182 (“the ’182 Patent”), 8,163,522 (“the ’522 Patent”), 7,915,225 (“the ’225…arthritis. The ’225 Patent, the ’605 Patent, and the ’631 Patent (“the Immunex Patents”), owned by Immunex…States Patent Nos. 8,063,182 (“the ’182 Patent”) and 8,163,522 (“the ’522 Patent”) (collectively… Patent”), and 8,722,631 (“the ’631 Patent”) (collectively, “the Immunex Patents”). External link to document
2019-12-23 107 Amended Complaint control element Such as, for U.S. Pat. No. 6,235,883 B1. Human antibodies can also be … 18 those described in U.S. Pat. No. 6,235,883 B1, incorporated encoding the human… U.S. Patent No. 8,063,182 (“the ’182 Patent”), • U.S. Patent No. 8,163,…Roche Patents”), • U.S. Patent No. 6,872,549 (“the ’549 Patent”), … U.S. Patent No. 6,924,124 (“the ’124 Patent”), • U.S. Patent No. 7,157, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Express Scripts
Colorcon
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.